CN112334475B - Bcl6抑制剂 - Google Patents
Bcl6抑制剂 Download PDFInfo
- Publication number
- CN112334475B CN112334475B CN201980039513.4A CN201980039513A CN112334475B CN 112334475 B CN112334475 B CN 112334475B CN 201980039513 A CN201980039513 A CN 201980039513A CN 112334475 B CN112334475 B CN 112334475B
- Authority
- CN
- China
- Prior art keywords
- amino
- chloro
- quinolin
- methyl
- oxazepine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202411445401.8A CN119330979A (zh) | 2018-04-13 | 2019-04-12 | 作为bcl6抑制剂的化合物及其制备方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1806132.5 | 2018-04-13 | ||
| GBGB1806132.5A GB201806132D0 (en) | 2018-04-13 | 2018-04-13 | Inhibitor coumpounds |
| GBGB1819136.1A GB201819136D0 (en) | 2018-11-23 | 2018-11-23 | Inhibitor compounds |
| GB1819136.1 | 2018-11-23 | ||
| PCT/GB2019/051058 WO2019197842A1 (en) | 2018-04-13 | 2019-04-12 | Bcl6 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411445401.8A Division CN119330979A (zh) | 2018-04-13 | 2019-04-12 | 作为bcl6抑制剂的化合物及其制备方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112334475A CN112334475A (zh) | 2021-02-05 |
| CN112334475B true CN112334475B (zh) | 2024-10-29 |
Family
ID=66240166
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980039513.4A Active CN112334475B (zh) | 2018-04-13 | 2019-04-12 | Bcl6抑制剂 |
| CN202411445401.8A Pending CN119330979A (zh) | 2018-04-13 | 2019-04-12 | 作为bcl6抑制剂的化合物及其制备方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202411445401.8A Pending CN119330979A (zh) | 2018-04-13 | 2019-04-12 | 作为bcl6抑制剂的化合物及其制备方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11512095B2 (OSRAM) |
| EP (3) | EP4729127A2 (OSRAM) |
| JP (2) | JP7493454B2 (OSRAM) |
| KR (2) | KR20250105504A (OSRAM) |
| CN (2) | CN112334475B (OSRAM) |
| AU (2) | AU2019253510B2 (OSRAM) |
| BR (1) | BR112020020832A2 (OSRAM) |
| CA (1) | CA3095371A1 (OSRAM) |
| DK (1) | DK3774817T3 (OSRAM) |
| ES (2) | ES2939776T3 (OSRAM) |
| HR (1) | HRP20230120T1 (OSRAM) |
| IL (2) | IL296734B2 (OSRAM) |
| MX (2) | MX2020010805A (OSRAM) |
| PT (1) | PT3774817T (OSRAM) |
| SG (1) | SG11202009735QA (OSRAM) |
| WO (1) | WO2019197842A1 (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019253510B2 (en) * | 2018-04-13 | 2023-08-10 | Cancer Research Technology Limited | BCL6 inhibitors |
| GB201909573D0 (en) | 2019-07-03 | 2019-08-14 | Cancer Research Tech Ltd | Modulation of T cell cytotoxicity and related therapy |
| GB201914860D0 (en) * | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
| US12310975B2 (en) * | 2019-10-17 | 2025-05-27 | Arvinas Operations, Inc. | Modulators of BCL6 proteolysis and associated methods of use |
| CA3214806A1 (en) | 2021-04-16 | 2022-10-20 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| CR20250001A (es) | 2022-06-06 | 2025-05-14 | Treeline Biosciences Inc | Degradadores bifuncionales de bcl6 de quinolona tricíclica |
| JP2025525324A (ja) | 2022-06-13 | 2025-08-05 | ツリーライン バイオサイエンシズ インコーポレイテッド | １，８－ナフチリジン－２－オンヘテロ二官能性ｂｃｌ６分解剤 |
| AU2023292893A1 (en) | 2022-06-13 | 2025-01-02 | Treeline Biosciences, Inc. | Quinolone bcl6 bifunctional degraders |
| JP2025524835A (ja) * | 2022-07-19 | 2025-08-01 | ダナ－ファーバー キャンサー インスティテュート，インコーポレイテッド | キノキサリンジオンおよびピリド［２，３－ｂ］ピラジン－２，３－ジオンｂ細胞リンパ腫６（ｂｃｌ６）分解剤ならびにその使用 |
| CN120813582A (zh) * | 2023-03-17 | 2025-10-17 | 西藏海思科制药有限公司 | 一种含氮三并环衍生物及其在医药上的应用 |
| WO2025049964A1 (en) * | 2023-09-01 | 2025-03-06 | Treeline Biosciences, Inc. | Bcl6 bifunctional degraders |
| AU2024331309A1 (en) * | 2023-09-01 | 2026-03-19 | Treeline Biosciences, Inc. | Tricyclic quinolone bcl6 bifunctional degraders |
| CN120987969A (zh) * | 2024-05-21 | 2025-11-21 | 中国药科大学 | 一类蛋白靶向降解嵌合体及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018108704A1 (en) * | 2016-12-13 | 2018-06-21 | Boehringer Ingelheim International Gmbh | New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors |
| WO2018215798A1 (en) * | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0259572A (ja) | 1988-08-23 | 1990-02-28 | Mitsubishi Kasei Corp | ベンズイミダゾロン誘導体又はその塩類 |
| GB9624482D0 (en) | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
| WO1997030035A1 (en) | 1996-02-13 | 1997-08-21 | Zeneca Limited | Quinazoline derivatives as vegf inhibitors |
| ES2169355T3 (es) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | Derivados de 4-anilinoquinazolina. |
| GB9718972D0 (en) | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
| GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
| AU760250B2 (en) | 1998-12-04 | 2003-05-08 | Neurosearch A/S | New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents |
| GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
| GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
| BRPI0017548B8 (pt) | 1999-02-10 | 2023-05-02 | Astrazeneca Ab | Composto |
| CZ2002233A3 (cs) | 1999-07-21 | 2002-04-17 | Fujisawa Pharmaceutical Co., Ltd. | Benzimidazolonové deriváty, způsob jejich výroby a farmaceutický prostředek |
| IL152682A0 (en) | 2000-05-31 | 2003-06-24 | Astrazeneca Ab | Indole derivatives with vascular damaging activity |
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| BR0112224A (pt) | 2000-07-07 | 2003-06-10 | Angiogene Pharm Ltd | Composto, composição farmacêutica, uso de um composto ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, processo para preparar um composto |
| HUP0301742A3 (en) | 2000-07-07 | 2005-08-29 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use |
| UY27304A1 (es) | 2001-05-24 | 2002-12-31 | Avanir Pharmaceuticals | Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación |
| AU2003231231A1 (en) | 2002-05-06 | 2003-11-11 | Bayer Pharmaceuticals Corporation | Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders |
| US7825132B2 (en) | 2002-08-23 | 2010-11-02 | Novartis Vaccines And Diagnostics, Inc. | Inhibition of FGFR3 and treatment of multiple myeloma |
| US20050256157A1 (en) | 2002-08-23 | 2005-11-17 | Chiron Corporation | Combination therapy with CHK1 inhibitors |
| CA2656507C (en) | 2006-07-17 | 2012-03-20 | Amgen Inc. | Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors |
| WO2008066887A2 (en) | 2006-11-30 | 2008-06-05 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of bcl6 |
| US8686008B2 (en) | 2007-08-16 | 2014-04-01 | The University Of Mississippi | Highly selective sigma receptor ligands |
| WO2009063240A1 (en) | 2007-11-16 | 2009-05-22 | Arrow Therapeutics Limited | 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase |
| US8071766B2 (en) | 2008-02-01 | 2011-12-06 | Takeda Pharmaceutical Company Limited | HSP90 inhibitors |
| EP2364983B1 (en) | 2008-11-11 | 2013-10-23 | Jeil Pharmaceutical Co., Ltd. | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same |
| PL2389372T3 (pl) | 2009-01-23 | 2016-02-29 | Rigel Pharmaceuticals Inc | Kompozycje i sposoby hamowania szlaku JAK |
| EA201290642A1 (ru) | 2010-01-13 | 2013-05-30 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Соединения и способы |
| ES2698847T3 (es) | 2011-07-07 | 2019-02-06 | Merck Patent Gmbh | Azaheterociclos sustituidos para el tratamiento del cáncer |
| CA2877146C (en) | 2012-06-18 | 2020-10-20 | Dart Neuroscience (Cayman) Ltd | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
| EP2964642B1 (en) | 2013-03-05 | 2017-11-15 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| US9943506B2 (en) | 2013-06-17 | 2018-04-17 | Cornell University | BCL6 inhibitors as anticancer agents |
| CN105017159B (zh) | 2014-04-28 | 2019-05-17 | 四川大学 | 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途 |
| ES2914099T3 (es) | 2014-08-25 | 2022-06-07 | Salk Inst For Biological Studi | Inhibidores novedosos de ULK1 y métodos de uso de los mismos |
| WO2016033416A1 (en) | 2014-08-29 | 2016-03-03 | Board Of Regents, University Of Texas System | Bromodomain inhibitors for treating disease |
| AU2015357498B2 (en) | 2014-12-06 | 2019-09-12 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2017007658A1 (en) | 2015-07-07 | 2017-01-12 | Rigel Pharmaceuticals, Inc. | A combination for immune mediated cancer treatment |
| AU2018274723B2 (en) | 2017-05-26 | 2024-01-18 | Cancer Research Technology Limited | Benzimidazolone derived inhibitors of BCL6 |
| GB201819136D0 (en) | 2018-11-23 | 2019-01-09 | Cancer Research Tech Ltd | Inhibitor compounds |
| AU2019253510B2 (en) | 2018-04-13 | 2023-08-10 | Cancer Research Technology Limited | BCL6 inhibitors |
| GB201914860D0 (en) | 2019-10-14 | 2019-11-27 | Cancer Research Tech Ltd | Inhibitor compounds |
-
2019
- 2019-04-12 AU AU2019253510A patent/AU2019253510B2/en active Active
- 2019-04-12 EP EP25225215.0A patent/EP4729127A2/en active Pending
- 2019-04-12 WO PCT/GB2019/051058 patent/WO2019197842A1/en not_active Ceased
- 2019-04-12 KR KR1020257022060A patent/KR20250105504A/ko active Pending
- 2019-04-12 US US17/046,650 patent/US11512095B2/en active Active
- 2019-04-12 CA CA3095371A patent/CA3095371A1/en active Pending
- 2019-04-12 BR BR112020020832-9A patent/BR112020020832A2/pt active Search and Examination
- 2019-04-12 KR KR1020207032149A patent/KR102830237B1/ko active Active
- 2019-04-12 ES ES19718834T patent/ES2939776T3/es active Active
- 2019-04-12 CN CN201980039513.4A patent/CN112334475B/zh active Active
- 2019-04-12 PT PT197188345T patent/PT3774817T/pt unknown
- 2019-04-12 IL IL296734A patent/IL296734B2/en unknown
- 2019-04-12 SG SG11202009735QA patent/SG11202009735QA/en unknown
- 2019-04-12 EP EP22211485.2A patent/EP4201939B1/en active Active
- 2019-04-12 EP EP19718834.5A patent/EP3774817B1/en active Active
- 2019-04-12 ES ES22211485T patent/ES3060268T3/es active Active
- 2019-04-12 JP JP2020555420A patent/JP7493454B2/ja active Active
- 2019-04-12 CN CN202411445401.8A patent/CN119330979A/zh active Pending
- 2019-04-12 DK DK19718834.5T patent/DK3774817T3/da active
- 2019-04-12 HR HRP20230120TT patent/HRP20230120T1/hr unknown
- 2019-04-12 MX MX2020010805A patent/MX2020010805A/es unknown
-
2020
- 2020-10-04 IL IL277778A patent/IL277778B2/en unknown
- 2020-10-12 MX MX2023004920A patent/MX2023004920A/es unknown
-
2022
- 2022-10-18 US US17/968,159 patent/US12486285B2/en active Active
-
2023
- 2023-11-09 AU AU2023263501A patent/AU2023263501B2/en active Active
-
2024
- 2024-05-21 JP JP2024082277A patent/JP7855637B2/ja active Active
-
2025
- 2025-10-03 US US19/349,679 patent/US20260042776A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018108704A1 (en) * | 2016-12-13 | 2018-06-21 | Boehringer Ingelheim International Gmbh | New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors |
| WO2018215798A1 (en) * | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7855637B2 (ja) | Ｂｃｌ６阻害剤 | |
| CN111163839B (zh) | 苯并咪唑酮衍生的bcl6抑制剂 | |
| CN110023315B (zh) | 新的化合物或其药理学上可接受的盐 | |
| US20120165313A1 (en) | Pyrimidine compounds, compositions and methods of use | |
| CN106459035B (zh) | N2‑苯基‑吡啶并[3,4‑d]嘧啶‑2,8‑二胺衍生物及其作为mps1抑制剂的用途 | |
| CN102480961A (zh) | 与含氧杂环稠合的嘧啶化合物、组合物和使用方法 | |
| CA2873975A1 (en) | Thienopyrimidines | |
| IL292182B1 (en) | History of [4,1]oxazepino[3,2-c]quinolinones as Bcl6 inhibitors | |
| HK40095873A (en) | Bcl6 inhibitors | |
| HK40046058A (en) | Bcl6 inhibitors | |
| HK40046058B (en) | Bcl6 inhibitors | |
| EA050300B1 (ru) | Ингибиторы bcl6 | |
| HK1160466A (en) | Pyrimidine compounds, compositions and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |